Jill Feldman: If I can help one person or one family – that matters
Jill Feldman, Co-Founder of EGFR Resisters and Lung Cancer Patient and Advocate, shared a post on LinkedIn:
“Sharing my story is never easy—it’s vulnerable and often feels like reliving the hardest moments of my life. But, I do it because if I can help one person or one family — THAT matters.
My story illustrates hope & progress, but it is part of a large and growing tapestry of countless stories that matter. I believe stories can change hearts and minds. They can educate, inspire, and bring change.
Thank you, The Patient Story, for sharing my story and many others that create understanding, bring hope, and inspire many.”
Jill Feldman is a lung cancer patient and advocate. She is the Co-Founder EGFR Resisters, an advocacy group of EGFR positive lung cancer patients who are resistant to targeted treatment. She is the Past President of the LUNGevity Foundation, Deputy Chair of IASLC’s patient advisory board and a member of The Chicago Institute of Translational Medicine’s patient advisory board. Jill is a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, a planning committee member on IASLC’s North America Conference on Lung cancer and as a member of the the ECOG-ACRIN Research Group’s patient advocate committee and thoracic committee.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023